Redeye updates on W5 post Q3-results which saw softer-than-expected topline while a strong gross margin resulted in a stronger-than-expected EBIT outcome. The order backlog remains solid and with substantial deliveries scheduled for Q4, the company looks set to deliver strong year-end performance.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/